Abstract Historically, large-scale longitudinal genomic research studies have not returned individual research results to their participants, as these studies are not intended to Wnd clinically signiWcant information for individuals, but to produce 'generalisable' knowledge for future research. However, this stance is now changing. Commentators now argue that there is an ethical imperative to return clinically signiWcant results and individuals are now expressing a desire to have them. This shift reXects societal changes, such as the rise of social networking and an increased desire to participate in medical decision-making, as well as a greater awareness of genetic information and the increasing ability of clinicians to use this information in health care treatment. This paper will discuss the changes that have prompted genomic research studies to reconsider their position and presents examples of projects that are actively engaged in returning individual research results.
Introduction
There has been considerable discussion regarding returning individual research results to participants in genomic research studies. The debates have focused on what constitutes a 'result', when should such Wndings be communicated, who has the ethical duty to disclose Wndings, and for which kinds of research study should they be disclosed. With large-scale longitudinal genomic research studies, data and samples are collected in a repository for use in future research studies. In this context, the policy has been that individual results would not be returned, either on grounds of cost or uncertainty regarding the value of the results in a clinical setting pending further veriWcation. However, this stance is now changing. In this article, we present the historic position taken by population biobanks, the new drivers that are pushing projects to either review their policies or build in procedures to deal with this issue, and examples of how some biobanks are moving forward in response.
Historic position
Population biobanks have traditionally provided two kinds of 'results' to participants. The Wrst are the results from the assessment that individuals undergo as part of joining the study. Individuals are usually given a series of tests and measurements, in addition to, in some cases, being asked to complete health and lifestyle questionnaires. Results from these initial assessments (e.g. blood pressure, BMI, and weight) can be given to the participant, at the end of their induction session, often in the form of a written summary. If during this preliminary session an assessment level is considered unsafe, biobank staV will direct the person to speak about the result to their general practitioner or, if necessary, urge them to go immediately to a hospital or clinic to have the problem investigated (Knoppers and Kharaboyan 2009 ). Many potential participants see these initial assessment results as an incentive to join the biobank. Godard et al. (2007) found that for participants in the CARTaGENE biobank, " [t] he most important criteria for participating in the…project would be the possibility of obtaining the results of the biochemical test performed at the time of the interview". Secondly, once the biobank's resources have been used by outside researchers, general results from these studies are provided to participants and others, through various media such as on the biobank's website, or as newsletters and leaXets that might be made available through medical professionals or through the post to participants. This reXects the ethical imperative to publish as well as a way to show respect for and acknowledge the eVorts of study participants.
On the other hand, it has been suggested that individual level research results, and particularly genetic information, not be fed back to participants (Beskow et al. 2001 ) and this has been reXected in the consent materials of biobanks (Wallace et al. 2009 ). There are several arguments for this. Population biobank studies are not intended to Wnd clinically signiWcant information for individuals, but to produce 'generalisable' knowledge for future research and therefore it could be argued that there is no case for returning results to individuals. As biobanks are designed as resources for future research, there is also the diYculty of securing adequate consent from participants with regard to as yet undiscovered outcomes, some of which might be highly signiWcant (e.g. a mutation in a dominant gene for an unsuspected late onset disorder) while others may be of more limited value, such as a slightly raised predisposition to a common disorder (CaulWeld et al. 2003) .
Commentators have also argued that the depth of the relationship between the researcher and the participant should be a factor in the feeding back of results (Ravitsky and Wilfond 2006; Beskow and Burke 2010; NHGRI Intramural Research Bioethics Core 2010) . When considering obligations such as returning results, "…researchers have a stronger moral responsibility to engage with a fuller range of participants' needs when the relationship is deeper" (Beskow and Burke 2010) . Conversely, when the relationship is more distant, this can mitigate the need to return results. This certainly could apply in the case of a healthy volunteer's data in a population biobank being used by a 'secondary researcher,' deWned as those researchers who are not involved in the original project but are "…accessing the data through managed data access mechanisms" (UK10K 2010). The relationship between a secondary researcher and a participant can be seen to be physically distant, if the research is taking place in another institution perhaps in another country; furthermore, the secondary research may take place long in the future, creating a gap between the time of joining the biobank and the time of the discovery.
A balance must also be struck between using resources to further the research and the costs associated with maintaining the option of re-contact with individual participants in the event of a signiWcant discovery emerging. Biobanks are expensive enterprises (Elliott and Peakman 2008) and some have argued that it is a mistake to stray from the goal of knowledge for the public good to that of beneWting individuals (Forsberg et al. 2009 ). Also, with early outcomes of uncertain value, initial Wndings need to be conWrmed by further research to avoid premature conclusions and prevent unnecessary alarm and invasive follow-up testing. Concern about the use of associations between observed changes in the genome and predictions about the consequent risks of common disease by companies selling genetic tests direct to the public has been raised by the UK Human Genetics Commission, resulting in the production of a code of conduct (Human Genetics Commission 2010) and by the US Secretary's Advisory Committee on Genetics, Health and Society (Secretary's Advisory Committee on Genetics Health and Society 2010). In addition, California and New York have ordered direct-to-consumer genetic testing companies to stop soliciting business from state residents (Langreth and Herper 2008; Pollack 2008) . The 'downstream' work to validate suspected Wndings has not been within the remit of the population studies themselves, but that of the researchers accessing the resource.
Commentators are also considering whether agreeing to return results might impose Wduciary duties on biobank administrators (Morreim 2005; Meltzer 2006 ). Therapeutic misconception (Appelbaum et al. 1982 ) is another concern. Studies have shown that, in the context of clinical trials, research participants do not always appreciate and understand the important diVerences between research and treatment (Henderson et al. 2007 ). If clinically relevant results are given to them, this may enhance any confusion.
However, many commentators now consider this position of not returning individuals results as untenable. Based on arguments of autonomy (Rothstein 2006 ) and the rejection of paternalism on the part of researchers (Fernandez 2008) , they argue that participants should be able to access their results. Moreover, the desire of individuals to receive their results when participating in research studies appears to be on the rise (Murphy et al. 2008; Meulenkamp et al. 2010) . The factors driving this change in attitude are varied, however, clues may be found in the parallel progression of changes in society, together with the increase of genetics knowledge, as a result of the completion of the Human Genome Project (HGP). These changes are forcing population biobanks to reconsider their stance on returning results.
New drivers
The (Lander 2011 ).
The ability to sequence a large number of base pairs at a relatively low cost is one of the drivers behind 'personalised medicine' (the ability to determine the right medicine for the right person at the right time) and 'personal genomics' ("the sequencing of an individual's genome for healthrelated enquiry or for determining genetic predisposition to disease"; Mardis 2011). Individuals such as James Watson, co-discoverer of the chemical structure of DNA, have had their genomes completely sequenced (Wheeler et al. 2008) , and the ability to sequence a person's genome raises the question of what to do with that information and how to communicate it (McGuire and Lupski 2010). Whole genome sequencing produces an enormous amount of data about an individual; at this point in time, much of it cannot be interpreted. However, the evidence base is growing and clinical applications are becoming more readily available.
Personal genomics companies now provide customers with a genotype proWle based on a selected number of single nucleotide polymorphisms (SNPs) that indicate a potential predisposition towards conditions and tendencies. For example, 23andMe will provide genetic analysis information on personal traits, cancer status, drug response and disease risk (23andMe 2011). While commentators debate the eYcacy and worthiness of such personal genomic proWles (Magnus et al. 2009; Samuel et al. 2010 ), 23andMe believes they are "…democratizing personal genetics and expanding the opportunity for more people to beneWt from the genetic revolution" (23andMe 2008). Claims of the predictive power of these DNA-based diagnostics may now be contributing to a climate of expectation about the utility of biobank-derived information. Thus, private practice (whether good or bad) appears to be driving public policy.
This desire for one's personal genome is one reXection of societal shifts over the last few decades. On one hand, genetics and genomics knowledge is increasing and becoming part of everyday language as well as more and more signiWcant in medical practice. In parallel, society has been changing from a position where a paternalistic view of life was accepted to one where people are taking greater individual control in their day-to-day lives. The rise of personal computing and social networking has changed the way in which individuals live their lives. Internet use has increased dramatically over the last decade and internet-based social networks, such as Facebook and Twitter, are now used extensively for casual as well as business uses. They are also used extensively as a part of social activism, as shown in the early-2011 uprisings in Egypt (Alexander 2011) . In medicine, patient activists are becoming more and more a part of the health care and drug development process; patient-driven medicine (or participatory medicine) is on the rise (Frydman 2009 With an increased knowledge of genetics, together with the growing ability to personally control one's environment, and the ability to contribute directly to the progress of medical research, it is not surprising that people are actively seeking personal health data. This includes participants in large-scale population biobank studies.
Public perceptions about the application of genetics in non-clinical contexts
Although biobanks are established for the purposes of facilitating research by others into the genetic components of health and disease, and because of this they generally beneWt from high levels of public support and legitimation, this cannot be taken for granted by those responsible for their establishment and future maintenance. The application of genetics in non-medical contexts is also on the increase, and this inevitably colours the perceptions of citizens, policy makers and regulators as to the potential risks and beneWts associated with this technology.
The depiction of forensic science on television, the use of forensic databases for the detection of crime, and the rise in DNA-based paternity testing have created a perception of certainty about the dependability of genetic information. The 'CSI EVect' deWned as "…the phenomenon in which jurors hold unrealistic expectations of forensic evidence and investigation techniques" (Robbers 2008 ) has been demonstrated to be real and is inXuencing not only jurors but the way in which judges and law enforcement oYcials act as well (Durnal 2010) . In the UK, public consultations do not focus on whether or not there should be a UK DNA Database, but rather how it should be constituted, used and governed (Human Genetics Commission 2009). The American Association of Blood Banks reported that relationship testing in its accredited laboratories has risen steadily from 1988 with 77,000 reported cases to almost 415,000 cases in 2008 (AABB 2008) .
Recreational uses, such as ancestry tracing, are also growing in popularity. The success of television shows such as 'Who Do You Think You Are?' has encouraged people to seek out their ancestors; many websites now exist that will provide information on your ethnic origins for a fee, although there is some dispute whether these services are accurate (GoVe 2009). Genealogical tourism to trace one's family history is a growing business, with people taking trips to visit ancestral lands as well as to visit genealogical libraries for research purposes (Santos and Yan 2010). Santos and Yan postulate that "…by fashioning group distinctiveness and drawing on ancestry, one is able to rescue one's individuality," a commodity that is being eroded in modern society (Santos and Yan 2010) . This sense of individuality goes one step further with the introduction of genetic testing. Vendors are now providing the DNA test, the subsequent ancestral data analysis and the appropriate travel arrangements to visit the land of one's ancestors in one complete package (Naish 2010) .
The search for one's genetic roots can have unsuspected and sometimes unwelcome ramiWcations. The consequences of the revelation that one's biological father is not the same as one's social father can be devastating for a family (with the risks of discovering unexpected "discontinuities" in ones lineage either ignored or even made light of-a recent UK TV advertisement for one of these services introduced the milkman as an ancestor; Genes Reunited 2010). As well, there is continued speculation about the potential for insurers to use genetic information to exclude people at risk from cover (Joly et al. 2010 ). This has led to restrictions on access by insurers based on either voluntary codes such as the concordat and moratorium between the UK Government and the Association of British Insurers (HM Government and Association of British Insurers 2005), recently extended until 2017 (Association of British Insurers 2011), or on statutory prohibition such as the Genetic Information Non-Discrimination (GINA) Act in the US (GINA 2008) . Despite these measures, suspicion of insurers' intentions remains widespread and this is reXected in often inconsistent attitudes to the use of genetic information by public and private bodies on the part of individuals and groups.
Guidance for returning results
Outside of population biobanks, many organisations have considered the implications and processes related to returning individual research results, especially genetic results (Knoppers et al. 2006; Dressler 2009; NHGRI Intramural Research Bioethics Core 2010) . As far as the process is concerned, it is recommended that researchers "…should have a clearly articulated policy on feedback and the nature of the feedback, if any, that will be provided to participants" (OECD 2009). Common, if not unanimous, agreement can be found on the conditions and processes that might make up this policy:
• The IRB, the researcher, and other appropriate experts are responsible to make the determination about disclosure.
• Research subjects need to be given an opportunity to decide whether they want to receive the research results.
• Informed consent process and document should indicate if disclosure is planned or likely and describe the risks associated with disclosure.
• Only professionals capable of providing genetic counselling should give genetic or genomic research results.
• Counselling of patients before and after receiving research result is required.
• Oversight of the disclosure process is required (Dressler 2009 ).
If there is an agreed plan for disclosure, it needs to be approved by an ethics review board and made clear to potential participants. In addition, any results should be determined to be analytically and clinically valid. Some commentators believe that there should also be some form of medical intervention to oVer the individual; others believe that this is not a requirement, especially when there are no known or no eVective interventions (Dressler 2009 ). Regardless, the participant needs to have been told whether there is a possibility of results being returned and asked for their consent. If they decide they do not wish to know, this should be respected. If the decision is taken to not return results to individuals, this too must be made clear to potential participants.
Examples from biobanks and other large-scale genetic research studies
These guidelines are of general use to a population biobank; however, they are not completely appropriate, as they do not Wt with the structure and mission of a biobank and thus create potential diYculties. As mentioned, biobanks are not designed to be concerned with the health care needs of individuals and will generally not have the resources, such as the services of genetic counsellors, available to them. But if they wish to address this issue, population biobanks need to consider how to include the potential for immediate individual beneWt into the structure of a population-based resource being created for future unknown research. With no speciWc guidance to draw from, population biobanks are looking at old and new practices, being used by other biobanks and longitudinal studies, from which they can tailor their own policies.
Returning results through a general practitioner
LifeLines, hosted by the University of Groningen, The Netherlands, is "a cohort study to investigate universal risk factors and their modiWers for multifactorial diseases" (Stolk et al. 2008) . Participants are recruited, for the most part, through their general practitioner (GP) and it is through this relationship that the results process is managed. The LifeLines researchers worked with the recruiting GPs to deWne cutoV levels for assessment information (e.g. blood pressure and serum glucose results). If one of these assessment levels causes concern, the participant will receive a letter telling them that they should contact their GP to discuss it, while their GP receives a letter with the actual results. SpeciWc genetic information is not returned so that the individual can say that they have not had genetic testing, as this has implications related to insurance. If LifeLines researchers discover validated and clinically signiWcant information that will have an inXuence on a participant's health, it is reported to their GP, who will then discuss it with them.
This model provides a bridge between the biobank and the participant recruited through the GP and relies on the strength of the GP-patient relationship that exists in many parts of the world to provide an avenue for returning of results. It would certainly seem logical that primary care settings, where the relationship between the GP and individual is clear and may be long-standing, would be the appropriate setting for receiving and discussing clinically signiWcant, and perhaps life-altering, health information. However, this depends on the health care system having an emphasis on continuity between a GP and a patient, a situation that might not exist in all countries.
Returning results directly to individuals after consideration by an oversight committee Researchers look to their ethics review board for assistance in deciding how to handle questions of ethical conduct in research. However, these boards are responsible for approving, and in some cases monitoring, hundreds of research projects. They may not have the time or expertise to deal with the speciWcs of returning results in one speciWc study, especially if that is a large-scale population-based study with thousands of participants. Therefore, some projects create internal committees, similar to data monitoring or data access committees that work together with the executive committee of the biobank and the responsible ethics review bodies. Kohane et al. (2007) have suggested the model of an Informed Cohort Oversight Body (ICOB), an independent body responsible for returning results to participants. This body would be composed of various experts, including ethicists, geneticists, and patients, who would make decisions regarding which results would be returned and how it would be done. This model is now being put into practice.
The Coriell Personalized Medicine Collaboration (CPMC) is "…an evidence-based research study designed to determine the utility of using personal genome information in health management and clinical decision-making" (CPMC 2011). It is not a population biobank, but a longitudinal study using the ICOB model to oversee the return of results. The study aims to recruit 100,000 adults (over age 18) from in and around the Delaware Valley, in the northeastern part of the US. Study researchers are investigating the impact of personalised genetic information on people's health and whether it can indeed be used to improve outcomes. With consent, saliva is collected from volunteers. An online account is created for each participant where that person completes health questionnaires. The saliva sample is genotyped to determine genetic variations and a personalised genetic report is made available online to the participant. This report will contain risk information on various conditions as well as how the individual may react to certain medications (named drug-gene pairs by CPMC). Participants are then able to discuss their reports with their GP, family member or a genetic counsellor and make health care decisions accordingly. They can also allow secondary researchers access to their coded data. The CPMC has formed an ICOB to review the state-of-the-science; only those drug-gene pairs and genetic variants for health conditions approved by the ICOB will be given out. Their criteria for approving which conditions and gene variants it will return are the association between the variation and the condition and the actionability of the variant and the interventions available. Approved conditions include agerelated macular degeneration, coronary heart disease and melanoma. Study researchers will follow participants over the course of a minimum of 5 years, asking for updated medical information and how they have used their personal genetic information.
A consortium of biobanks is also using an oversight committee in its work, also related to electronic medical records. The eMERGE (Electronic Medical Records and Genomics) network is a US-based, "…national consortium formed to develop, disseminate, and apply approaches to research that combine DNA biorepositories with electronic medical record (EMR) systems for large-scale, highthroughput genetic research" (eMERGE Network 2011). eMERGE brings together Wve projects, each of which "…study the relationship between genome-wide genetic variation and a common disease/trait" (McCarty et al. 2011) . As part of their study, they have established several working groups, one of which is the Return of Results Oversight Committee. As this committee is new and has not as yet published policies, the processes it will choose to suggest to its member biorepositories are unknown at this time. However, rather than not return results as it had done in the past, its proposed informed consent language clearly states that contact may be made with participants:
"You should not expect to get individual results from research done through the Biobank. Researchers must study samples and information from many people over many years before they can know if the results have meaning. We will not give the results to your doctor. We will not put them in your medical record. There is a small chance that researchers could discover something that might be very important to your health or medical care right now. If this happens, we will contact you to see if you want to learn more" (eMeRGE Network 2009).
Returning all information to participants
The previous two models reXect the position that health care and other related professionals are necessary to act as gatekeepers between the science and the individual and make decisions as to what information that individual should receive. The Personal Genome Project (PGP) takes an alternative position on this subject. While not strictly a large-scale population biobank, this cohort study is recruiting participants "…to contribute genomic sequence data, tissues, and extensive environmental, trait, and other information to a publicly accessible and identiWable research database" (Lunshof et al. 2010) . Their aim is to enrol 100,000 participants who will openly share their genomic and health-related information as well as their experiences as a participant. PGP researchers give participants a Preliminary Research Report that includes the genetic variants that have some likelihood of clinical relevance and instructs them to conWrm anything potentially signiWcant with their GP or care provider. In this process, the intermediary is removed and the participant has control of the information, although there is still an acknowledgement that a health professional is necessary for interpreting the data. However, when it comes to the work of secondary researchers, the PGP states in its consent form that:
Generally, the PGP will not provide you with the results of any analysis, development or other work performed by third parties with access to your tissues or cell lines. However, because such results may be made publicly available, and may be identiWed as deriving from your tissues or cell lines, you may become aware, even without your consent, of the results of such activities (PGP 2011).
Therefore, the PGP can be seen as akin to the traditional biobank in that it gives its members results of an assessment (albeit a much more extensive one), but does not return results from secondary researchers.
Returning no results
Longitudinal biobanks that have been recruiting for several years according to an agreed epidemiological strategy and consent procedures may decide not to, or may not be able to, change their long-standing position regarding returning results. For example, UK Biobank, which completed its recruitment of 500,000 participants in late 2010, has had a 'no-returns' policy since its beginning. It states on its website that while individuals will be given results from the assessment if they choose, they will not receive results from future research: "1.What will I get out of attending an appointment?
You will be helping in a research study aimed at improving the health of future generations. We will at the end of the visit give you a report of the results of some of the measurement undertaken -this will include your blood pressure, lung function, body mass index, % body fat, weight and height.
2.Will you tell me if you Wnd something wrong with me?
We will tell you if your blood pressure is particularly high or low or if your lung function is signiWcantly reduced. During the next 20-30 years, samples will gradually be analysed as the Biobank resource becomes available for medical research of all kinds, both in Britain and around the world. As this may be far in the future, and researchers will be analysing anonymised samples, we will be unable to inform you of any Wndings" (UK Biobank 2011).
Whether this policy will change in the future for this or any other long-standing biobank is unknown. If a biobank does choose to revise its policy and address return of results, it will need to consider whether original consent materials allow for re-contact of participants. Re-contact is one provision longitudinal biobanks typically include in their consent materials (Cambon-Thomsen et al. 2007) , as this allows the biobank to ask participants for additional data from health records or if they wish to participate in speciWc research studies.
The future for population biobanks
This is a new issue for population biobanks and few details have been published. This paper has used examples from other large-scale longitudinal studies as well as biobanks, to show how study organisers are beginning to integrate returning results into their practice. Some studies are creating committees to consider queries from researchers who may be wondering whether certain information should be returned to a biobank participant. Oversight boards are being used to assist researchers in decisions regarding which variant information should be given to participants. However, the evidence is limited at this stage and biobanks need to carefully plan how they will deal with this issue and have any procedures reviewed and approved by their ethics review board. Consent materials should make clear whether any results will be returned to participants and if so, how it will be done. Re-contact measures will need to be discussed. Regardless, returning results should not be used as an incentive to join a study, as this is inconsistent with the nature of these kinds of studies (Knoppers and Laberge 2009) and it may introduce confusion amongst participants (e.g., joining for potential medical beneWt rather than as an altruistic act to support research for the beneWt of future generations).
Biobank administrators must be aware that even the 'best laid plans' need some Xexibility. Time should be dedicated to anticipating future contingencies; long-term population studies will necessarily not produce results in the short term but one cannot know when a discovery will be made that will impact the lives and health of individuals. In addition, anecdotal evidence has shown that participants may demand results even if the policy of the project was not to disclose them, especially if researchers Wnd a mutation that might respond to a therapy or develop an intervention that might be beneWcial. Researchers agree that there is a moral imperative to return results that may signiWcantly impact an individual's life; how this will be done needs careful consideration.
Conclusions
Historical policies regarding the issue of whether or not results should be returned to research subjects by biobanks or by the researchers using biobank samples and data have been deliberately cautious. In part, this has been due to justiWable concerns regarding the validity and the signiWcance of such results and the need for further validation before they can be used as a basis for action by research participants and/or clinicians. In part this has been for ethical concerns about the release of information to individuals who have not asked for it and may not want it, and in part it has been for practical reasons arising from the cost and the logistical diYculty of organising an appropriate procedure.
These assumptions are increasingly being challenged. Public perceptions regarding ownership of genetic information-"It's my genome and I am entitled to have the information in it"-and professional anxieties about the ability of sample donors to handle complex information of uncertain value are shifting. Novel communication possibilities are opening up cost eVective ways of disseminating information to individuals, groups or populations. Advances in genetics and genomics are increasing the probability of unanticipated information being revealed (some are talking of the $100 genome being a reality in the foreseeable future), and practices in the private sector regarding genetic predisposition testing are inXuencing public expectations with regard to the outputs from public sector biobanks.
It is clear that the historical dam, behind which the Xow of genetic and genomic data was held until it could be released in a carefully controlled manner to a few licensed recipients, will come under increasing pressure and may well prove to be unsustainable-even if society deems it desirable to do so. Policies for the return of Wndings to research participants must be subjected to regular review and where appropriate and necessary, amended to reXect changing circumstances and possibilities. In so doing, researchers can consistently demonstrate Wtness for purpose, securing public trust in the operation of biobanks, and hence contribute to the sustainability of these valuable yet expensive resources.
